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Abstract
Background: Paraoxonase-1 (PON1) is an antioxidant enzyme, that resides on high-density lipoprotein (HDL). PON1-activity,
is heavily influenced by the PON1-Q192R polymorphism. PON1 is considered to protect against atherosclerosis, but it is
unclear whether this relation is independent of its carrier, HDL. In order to evaluate the atheroprotective potential of PON1,
we assessed the relationships among PON1-genotype, PON1-activity and risk of future coronary artery disease (CAD), in a
large prospective case-control study.
Methodology/Principal Findings: Cases (n=1138) were apparently healthy men and women aged 45–79 years who
developed fatal or nonfatal CAD during a mean follow-up of 6 years. Controls (n=2237) were matched by age, sex and
enrollment time. PON1-activity was similar in cases and controls (60.7645.3 versus 62.6645.8 U/L, p=0.3) and correlated
with HDL-cholesterol levels (r=0.16, p,0.0001). The PON1-Q192R polymorphism had a profound impact on PON1-activity,
but did not predict CAD risk (Odds Ratio [OR] per R allele 0.98[0.84–1.15], p=0.8). Using conditional logistic regression,
quartiles of PON1-activity showed a modest inverse relation with CAD risk (OR for the highest versus the lowest quartile
0.77[0.63–0.95], p=0.01; p-trend=0.06). PON1-activity adjusted for Q192R polymorphism correlated better with HDL-
cholesterol (r=0.26, p,0.0001) and more linearly predicted CAD risk (0.79[0.64–0.98], p=0.03; p-trend=0.008). However,
these relationships were abolished after adjustment for HDL (particles-cholesterol-size) and apolipoproteinA-I (0.94[0.74–
1.18], p-trend=0.3).
Conclusions/Significance: This study, shows that PON1-activity inversely relates to CAD risk, but not independent of HDL,
due to its close association with the HDL-particle. These data strongly suggest that a low PON1-activity is not a causal factor
in atherogenesis.
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Introduction
Oxidation of low-density lipoprotein (LDL) and the subsequent
generation of lipid hydroperoxides has been shown to accelerate
the development of atherosclerosis and to adversely affect
cardiovascular outcome [1–3]. Consequently, a robust number
of antioxidants that potently inhibit LDL-oxidation in vitro [4,5]
have been tested in clinical trials of impressive size, but most of
these studies have yielded negative results [6–9]. Consequently,
attention has shifted towards other physiological targets that may
play a role in LDL-oxidation in vivo. In this respect, paraoxonase1
(PON1), a plasma enzyme that resides on the high-density
lipoprotein (HDL) particle, has been shown to inhibit LDL-
oxidation and is therefore also a strong candidate as a protective
enzyme in the development of atherosclerosis [10–12].
Interestingly, two genetic variants of PON1, the Q192R and
L55M polymorphisms (rs662 and rs854560, respectively) profound-
ly affect the activity of serum paraoxonase. The PON1-192 QQ
gene product exhibits low hydrolytic activity towards paraoxon,
whereas that of the RR-genotype shows high activity towards
paraoxon [13,14]. Conversely, the isoenzyme corresponding to this
RR-genotype exhibits low hydrolytic activity towards lipid hydro-
peroxides. Likewise, gene products of the PON1-55 LL-genotype,
LM-genotype and MM-genotype exhibit high, intermediate and
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many association studies have reported on PON1-gene polymor-
phisms and CAD risk, these studies have yielded conflicting results;
these reports were statistically underpowered, studied different
ethnic and patient populations, utilized different sampling strategies
as well as different genotyping procedures. These impediments have
been discussed in a meta-analysis of association studies on PON1-
genotype and CAD risk [15]. In contrast to PON1-genotype, only
few studies have assessed the relationship between PON1-activity
and CAD risk. In a cross-sectional study, hydrolysis rates of PON1
towards paraoxon and diazoxon were significantly lower in people
with carotid disease than in controls [13]. Consistently, the
prospective Caerphilly study showed that low PON1-activity
towards paraoxon was associated with an increased risk of future
CAD [14]. In line, PON1 activity and concentration were
significantly lower in patients with severe coronary artery stenosis
[16], whereas another study found no association between PON1
activity and coronary artery calcification [17]. In addition to this,
elevated levels of PON1 activity healthy middle-aged women were
shown to be associated with increased CAD risk [18]. These
conflicting data have made it difficult to fully comprehend the role
ofPON1inatherosclerosis.Infact,itremainsuncertainwhetherthe
relation between PON1-activity and CAD risk is causal and
whether it is independent of other CAD risk factors such as HDL
cholesterol [15]. We used the concept of Mendelian randomization
to evaluate whether PON1-activity may play a causal role in
determining CAD risk [19]. We quantified the activity of PON1
towards paraoxon, determined two prominent genetic variants
affecting PON1-activity, and assessed the consistency and propor-
tionality of relationships between genotype, phenotype and risk of
future CAD. We studied these relationships in a case-control study
nested in the large, prospective EPIC (European Prospective
Investigation into Cancer and Nutrition)–Norfolk study cohort.
Results
Serum samples from 1138 cases and 2237 controls were
included in the analysis from which 1099 cases were matched to
two controls and 39 cases were matched to one control. The
Q192R and L55M polymorphisms were available for 1077 cases
(61 missing cases). The numbers in tables 1, 2, 3 may not add up to
the total number because of missing data. Matching ensured that
the distribution of age and sex was comparable between cases and
controls. As expected, individuals who developed CAD during
follow-up were more likely than controls to smoke and to have
diabetes mellitus (Table 1). The use of alcohol was comparable
between cases and controls. Likewise, in both men and women,
levels of total cholesterol, LDL-cholesterol, triglycerides (non-
fasting), apoB, systolic and diastolic blood pressure, BMI, waist
circumference and CRP were significantly higher in cases than in
controls, whereas HDL-cholesterol and apoA-I were significantly
lower in cases than controls. Serum PON1-activity was similar in
cases and controls (60.7645.3 versus 62.6645.8 U/L, P=0.3).
Sex-specific analyses revealed similar results. Interestingly, women
had higher PON1-activity than men, consistent with higher HDL
cholesterol and apoA-I levels in women (see data supplement for
sex-specific data: Table S1). The distribution of PON1-Q192R
and PON1-L55M polymorphisms did not differ between cases and
controls (Table 1).
Table 2 shows the correlations between PON1-activity and risk
factors and associations between both PON1-genotypes and risk
factors. In brief, PON1-activity was positively correlated with
HDL-particle number, HDL-cholesterol, HDL-size, apoA-I, LDL-
cholesterol and vitamin-C concentration. There was a negative but
weak correlation with levels of CRP and MPO. Similar trends
were found among men and women in the sex-specific analyses
(see data supplement for sex-specific data: Table S2).
Although both genotypes were significantly associated with
PON1-activity, we found a stronger association for the PON1-
Q192R polymorphism. Carriership of more PON1-192R alleles
or more PON1-55M alleles was associated with a higher serum
PON1-activity, concordant with a gene-dosing effect. Distribution
of PON1-activity over genotypes was triphasic according to the
PON1-Q192R polymorphism, illustrating the strong influence of
this variant on the PON1-activity phenotype (Figure 1). Statistical
adjustment for the PON1-Q192R polymorphism yielded a
Table 1. Baseline characteristics of study participants.
Controls Cases P
Total no. of patients, n 2237 1138
Age, years 65686 5 68 Matched
Women, n (%) 768 (40) 384 (40) Matched
Body mass index, kg/m2 26.363.5 27.363.9 ,0.0001
Waist circumference, cm 91611 94612 ,0.0001
Smoking – – ,0.0001
-Never smoked, n 894 361 –
-Previous smoker, n 1138 592 –
-Current smoker, n 181 172 –
Alcohol use, units/week 7.469.5 6.6610.0 0.07
Vitamin supplement use, n (%) 964 (43) 476 (42) 0.5
Vitamin C, mmol/l 52620 46620 ,0.0001
Diabetes, n (%) 41 (2) 75 (7) ,0.0001
Systolic blood pressure, mmHg 139618 144619 ,0.0001
Diastolic blood pressure, mmHg 84611 86612 ,0.0001
Total cholesterol, mmol/l 6.361.2 6.561.2 ,0.0001
LDL-cholesterol, mmol/l 4.161.0 4.361.0 ,0.0001
HDL-cholesterol, mmol/l 1.3760.40 1.2760.37 ,0.0001
Triglycerides, mmol/l 1.6 (1.1–2.7) 1.9 (1.2–3.3) ,0.0001
Apolipoprotein B, mg/dl 129631 139634 ,0.0001
Apolipoprotein A-I, mg/dl 162629 155629 ,0.0001
HDL size, nm 8.9260.48 8.8260.46 ,0.0001
HDL particle number, nmol/L 34.265.5 33.365.9 ,0.0001
C-reactive protein, mg/l 1.5 (0.9–3.4) 2.4 (1.0–5.3) ,0.0001
Myeloperoxidase, pmol/l 534 (323–855) 607 (348–858) ,0.0001
Paraoxonase-1 activity, U/L 62.6645.8 60.7645.3 0.3
PON1-192 genotype 0.9
-PON1-192 QQ, n 1092 548 –
-PON1-192 QR, n 847 415 –
-PON1-192 RR, n 177 92 –
PON1-55 genotype 0.4
-PON1-55 LL, n 869 424 –
-PON1-55 LM, n 932 486 –
-PON1-55 MM, n 263 140 –
Data are presented as mean (6SD) or number (percentage). Data for C-reactive
protein, myeloperoxidase and triglycerides are presented as median
(interquartile range). P-values are for mixed effects model with continuous
variables, and for conditional logistic regression with dichotomous variables.
LDL=low-density lipoprotein, HDL=high-density lipoprotein cholesterol.
doi:10.1371/journal.pone.0006809.t001
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proxy for PON1-concentration. PON1-activity adjusted for the
PON1-Q192R polymorphism was similar in cases and controls
(0.4961.09 versus 0.7660.79 AU/L, P=0.8).
Table 3 shows the distribution of cardiovascular risk factors as
stratified by PON1-activity quartiles (Table 3) and the PON1-
Q192R polymorphism adjusted PON1-activity quartiles (Table 4).
In brief, in both men and women, the PON1-Q192R polymor-
phism adjusted PON1-activity showed a strong association with
HDL-cholesterol, HDL-particle number and apoA-I. There was a
modest inverse, but significant linear relationship between the
PON1-Q192R polymorphism adjusted PON1-activity and waist
circumference, CRP, MPO and age, whereas a modest positive
linear relationship was observed for gender, diabetes mellitus, total
cholesterol, LDL-cholesterol, plasma vitamin-C concentration and
HDL-size. Similar, although weaker, associations were found for
the unadjusted PON1-activity quartiles (Table 4).
Table 5A shows the unadjusted and adjusted ORs for future
CAD by quartiles of PON1-activity. Serum PON1-activity was
modestly, although not linearly related to risk of future CAD.
Adjustment for HDL-parameters (HDL-cholesterol, HDL-particle
number, HDL-size and apoA-I), did not considerably affect the
risk estimate. Further adjustment for risk factors (alcohol use, BMI,
CRP, diabetes mellitus, fasting time, LDL-cholesterol, MPO,
smoking, systolic blood pressure, plasma vitamin-C, vitamin
supplement use, waist circumference and triglycerides (non-fasting)
did not substantially alter the observed relationship.
Table 5B shows, however, that the PON1-Q192R polymor-
phism adjusted PON1-activity was strongly inversely related with
the risk of future CAD (OR 0.79 for the highest versus the lowest
quartile, 95% CI 0.64 to 0.98, P for linearity=0.008). This
relation was abolished by adjustment for HDL related parameters
(HDL-cholesterol, HDL-particle number, HDL-size and apoA-I).
Additional adjustments for cardiovascular risk factors did not
affect the results. Similar trends were found among men and
women in the gender-specific analyses (see data supplement for
gender-specific data: Table S3).
Backward stepwise regression analysis for PON1-activity,
PON1-genotype as well as PON1-activity adjusted for PON1-
192 and PON1-55 genotype revealed no significant effect of these
variables and CAD risk (see data supplement: Table S4, S5, S6).
Haplotypes of PON1-192 and PON1-55 genotypes where
equally distributed between cases and controls. Further the effect
of these different haplotypes on PON1 activity, PON1-genotypes
and PON1-activity adjusted for PON1-192 genotype are reported
in the supplementary table (see data supplement: Table S7). No
significant relation between combined haplotypes and CAD risk
was found.
Discussion
In this large prospective case-control study among apparently
healthy men and women, we observed that PON1-activity was
modestly and inversely related with the risk of future CAD.
However, given the fact that the Q192R polymorphism strongly
affects lifelong PON1-activity, the absence of a relation between
the Q192R polymorphism and CAD risk suggests that PON1-
activity is not a causal factor in atherogenesis. The apparent
protective function of PON1 can only be appreciated against the
background of its close association with HDL.
Whereas PON1-L55M genotype was modestly associated with
PON1-activity in our study, the PON1-Q192R polymorphism was
the strongest determinant of PON1-activity against paraoxon.
Although higher PON1-activity against paraoxon tended to be
associated with a lower CAD risk, this relation was not linear. More
importantly, PON1-Q192R genotype had no effecton CADrisk. In
the context of Mendelian randomization [19], these findings suggest
that the relation between PON1-activity against paraoxon and
CAD risk is not causal. Had this been the case, one would expect
consistent and proportional relationships among genotype, pheno-
type and CAD risk. We observed that carriership of a 192R allele
was associated with a 62.5 U/l increase in PON1-activity per allele.
In turn, an increase of 62.5 U/l in PON1-activity corresponds
approximately to the difference between the first and third PON1
Table 2. Associations between PON1 activity, PON1 genotype and risk factors.
R (activity) P * 192QQ 192QR 192RR P
{ 55LL 55LM 55MM P
{
No. of subjects, n 3375 1640 1262 269 1293 1418 403
PON1-activity, U/l – – 27698 7 627 152645 ,0.0001 84651 54635 23614 ,0.0001
HDL-chol, mmol/l 0.156 ,0.0001 1.3360.40 1.3460.39 1.3460.38 0.8 1.3460.39 13360.39 1.2960.37 0.1
HDL-particles, nmol/l 0.191 ,0.0001 33.765.5 33.965.9 34.365.5 0.4 33.865.7 34.165.6 33.265.5 0.1
HDL-size, nm 0.059 ,0.0001 8.960.5 8.960.5 8.960.5 0.9 8.960.5 8.960.5 8.960.5 0.3
LDL-chol, mmol/l 0.067 0.001 4.161.0 4.161.0 4.261.0 0.7 4.161.0 4.161.0 4.161.0 0.9
TG, mmol/l 0.013 0.6 1.7 (1.1–3.0) 1.7 (1.1–2.9) 1.8 (1.1–3.1) 0.4 1.7 (1.1–3.0) 1.7 (1.1–2.9) 1.7 (1.1–3.1) 0.9
ApoA-I, mg/dl 0.123 ,0.0001 160629 160630 160628 0.9 160630 160629 157628 0.2
ApoB, mg/dl 0.026 0.4 132632 132633 133632 0.9 132633 132632 134633 0.7
CRP, mg/l 20.041 0.05 1.7 (1.0–4.6) 1.7 (1.0–4.6) 2.1 (1.0–5.4) 0.7 1.7 (1.0–4.8) 1.7 (1.0–4.6) 1.7 (1.0–4.5) 0.8
MPO, pmol/l 20.059 ,0.0001 560 (343–805) 562 (345–886) 532 (312–883) 0.4 557 (325–885) 560 (354–890) 555 (310–897) 0.8
Alcohol use, units/wk 0.029 0.5 7.3610.0 6.969.5 7.669.9 0.4 7.1610.0 7.269.8 7.669.5 0.2
Vitamin-C, mmol/l 0.056 0.010 50620 49620 50619 0.3 50620 49620 51619 0.2
Data are presented as mean (6SD) or number (percentage). Data for C-reative protein (CRP), myeloperoxidase (MPO) and triglycerides (TG) are presented as median
(interquartile range). R indicates two-tailed Pearsons (parametric) or Spearman’s (non-parametric e.g. CRP, MPO and TG) correlation between PON1-activity and risk
factors with the corresponding p-value (P*). Associations between PON1-genotype and risk factors are indicated by the p-values between groups (P
{) from a one-way
ANOVA.
doi:10.1371/journal.pone.0006809.t002
PON1 and Future Risk of CAD
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6809activity quartile, which was associated with an OR for CAD of
0.81(95% CI [0.67–0.99]). However, carriership of a 192R allele
wasnotassociated witha proportionaldecreaseinCADrisk.Infact,
we observed a null relationship (OR 0.98[0.84–1.15], p=0.8). The
present findings imply that previous findings of an inverse relation
between PON1 activity and CAD risk were troubled by
confounding. In this respect, several issues deserve closer attention.
PON1 is located predominantly on HDL-particles. Since HDL has
a strong inverse relation to CAD risk [24], other protective effects
mediated by or associated with HDL [25] are likely to contribute to
the PON1–CAD relation. People with more circulating HDL-
particles can be expected to have a higher plasma PON1-
concentration. Because PON1-activity is a function of PON1-
concentration and PON1-genotype [26–27], we could obtain a
proxy for PON1-concentration by statistically adjusting PON1-
activity for the PON1-Q192R polymorphism. Indeed, the PON1-
Q192R polymorphism adjusted PON1-activity correlated better
with HDL-related parameters than unadjusted PON1-activity did.
Similarly, it was a better predictor of CAD risk than unadjusted
PON1-activity. However, statistical adjustment for HDL-related
parameters abolished the inverse relation between PON1-activity
adjusted for the PON1-Q192R polymorphism and CAD risk in the
present cohort(Table4B).Thesefindingslendfurthersupporttothe
concept that the relation between PON1-activity and CAD risk to a
relevant extent confounded by HDL-cholesterol levels and is not
based on causality.
PON1 and CAD risk
Numerous studies have reported associationsbetweenthe PON1-
Q192R and L55M polymorphisms and risk of CAD [28–34],
whereas other studies found no such relation [35–39]. However, a
meta-analysis reported no significant association for the L55M
variant [15]. In addition, it observed that the significant association
for the Q192R variant was largely explained by small studies while
larger studies which are less prone to statistical bias, showed no
significant association. Interestingly, recent genome-wide associa-
tion studies support our findings and have not revealed any
associations between the PON1-genotype and risk of CAD [40,41].
In addition, Jarvik et al. have shown that PON1-activity towards
paraoxon is a better predictor of cardiovascular risk than PON1
genotype [13]. In the present study, we substantiate this finding,
since no relationship was observed between the PON1-Q192R or
Table 3. Distribution of cardiovascular risk factors by quartiles of PON1 activity.
PON1- activity (U/l) 1
st quartile 2
nd quartile 3
rd quartile 4
th quartile PR P
{
Variable (,25.9) (25.9–43.0) (43.0–89.9) (.89.9)
Total no. of patients 844 844 844 843 – – –
Age, years 65.967.6 65.367.8 65.367.8 64.867.8 0.03 20.058 ,0.0001
Women, n (%) 248 (29) 342 (41) 281 (33) 368 (44) ,0.0001* 0.083 ,0.0001
Body mass index, kg/m2 26.763.7 26.663.6 26.663.6 26.763.7 0.9 0.001 0.9
Waist circumference, cm 93.5611.6 91.5611.7 92.6611.8 91.6611.4 0.001 20.043 0.01
Cigarette smoking 0.09* – –
-Never smoked, n 296 322 305 332 – – –
-Previous smoker, n 440 442 425 423 – – –
-Current smoker, n 98 70 103 82 – – –
Alcohol use, units/week 7.069.7 7.369.7 6.769.8 7.469.7 0.3 0.029 0.1
Vitamin supplement use, n (%) 342 (41) 377 (45) 360 (43) 361 (43) 0.4* – –
Plasma Vitamin C, mmol/l 48.8620.0 51.6620.1 47.6619.6 52.16619.2 ,0.0001 0.056 ,0.0001
Diabetes mellitus, n (%) 39 (5) 28 (4) 30 (3) 19 (3) 0.07* – –
Systolic blood pressure, mmHg 140618 141619 141618 141618 0.9 0.009 0.6
Diastolic blood pressure, mmHg 84612 856612 85611 84611 0.8 0.012 0.5
Total cholesterol, mmol/l 6.261.1 6.461.1 6.261.2 6.661.2 ,0.0001 0.112 ,0.0001
LDL-cholesterol, mmol/l 4.161.0 4.2661.0 4.161.0 4.361.0 ,0.0001 0.067 ,0.0001
HDL-cholesterol, mmol/l 1.2460.37 1.39660.39 1.3060.38 1.4360.40 ,0.0001 0.156 ,0.0001
Triglycerides, mmol/l 1.8 (1.1–2.4) 1.7 (1.1–2.3) 1.7 (1.1–2.5) 1.7 (1.1–2.4) 0.4 0.013 0.5
Apolipoprotein B, mg/dl 132632 132631 131634 135632 0.1 0.026 0.2
Apolipoprotein A-I, mg/dl 155629 162628 155629 166630 ,0.0001 0.123 ,0.0001
HDL size, nm 8.860.5 8.960.5 8.960.5 8.960.5 ,0.0001 0.059 0.001
HDL particle number, nmol/L 32.465.3 34.565.4 33.065.7 35.665.7 ,0.0001 0.191 ,0.0001
C-reactive protein, mg/l 1.9 (0.9–4.2) 2.1 (1.0–4.7) 1.8 (1.0–4.6) 1.6 (1.0–4.2) ,0.0001 20.041 0.02
Myeloperoxidase, pmol/l 607 (342–802) 531 (337–825) 573 (325–751) 514 (340–762) ,0.0001 20.059 0.001
Paraoxonase activity, U/L 19.964.1 32.564.6 86.5613.6 127.0634.7 – – –
Values are mean (6SD) or number (percentage). Data for C-reactive protein, meyloperoxidase and triglycerides are presented as median (6interquartile range). P=p-
value for linearity between quartiles of PON1-activity and risk factor levels; R=Pearson’s (parametric variables) or Spearman correlation (non-parametric variables e.g. C-
reactive protein, meyloperoxidase and triglycerides) between PON1-activity and risk factors, and the corresponding p-value (P
{). LDL=low-density lipoprotein,
HDL=high-density lipoprotein. * indicates p-value by chi square test for dichotomous variables.
doi:10.1371/journal.pone.0006809.t003
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respect, it should be noted that the present study was a large
prospective case-control cohort, comprising 1138 cardiovascular
events, whereas other observational studies have used a small
sample size and/or a retrospective design.
Finally, the role of inflammation in atherosclerosis has been
substantiated in numerous studies. However, in the present study,
inflammatory markers such as CRP and MPO did not affect the
relation between PON1 and CAD risk. An explanation for this
finding might be the modest relation between both CRP and
MPO versus PON1 activity.
PON1 and Vitamins
Vitamin C intake has previously been shown to be associated
with increased PON1 activity [42]. In line, the present study
demonstrated that PON1 activity is primarily genotype depen-
dent, and is just modestly influenced by plasma vitamin C
concentration. It has been suggested that a reduction in oxidative
stress related to vitamin C intake may preserve PON1 activity. In
addition, it has been shown that those subjects using vitamin
supplements are more likely to engage in healthy lifestyles, of
which the factors are multivariate [43]. Thus, it is possible that
some factor correlated with vitamin intake is actually influencing
PON1 activity.
Study Limitations
The results of the present study should be considered in light of
its potential limitations. First, case ascertainment is an issue in the
design of every prospective study, including this one. However, a
validation study indicated that case ascertainment in our study was
at least equivalent to that of other large prospective cohort studies
[44]. Second, the findings of the present study apply to Caucasians
and should be carefully extrapolated to non-Caucasian popula-
tions, especially since PON1-genotype frequencies have been
reported to vary substantially between Caucasian and East Asian
populations (PON1-192RR homozygosity occurs in only about
10% of Caucasians, but in about 40% of East Asians). Also,
activities of PON1 towards other substrates than paraoxon, e.g.
lipid hydroperoxides, might have a distinctly different impact on
atheroprotection. Therefore we cannot exclude that other tests for
PON1 activity would yield different results. However, since the
PON1-192 RR genotype, apart from high reactivity towards
paraoxon, is also characterized by low reactivity towards lipid
hydroperoxides, the absence of a relationship between the PON1-
Q192R polymorphism and CAD risk suggests that this particular
phenotype can not strongly modulate CAD risk either. Third, the
in vitro hydrolysis of paraoxon reflecting PON1 activity may be a
suboptimal method to measure its actual in vivo antioxidant
capacity. Methods to more accurately PON1 in vivo antioxidant
capacity are currently not at hand.
Fourth, a common limitation of case-control studies, even when
they are of a prospective nature is that subjects who contract CAD
at a future date are bound to have more classical risk factors than
subjects who do not. This may limit the contribution of PON1-
activity and genotype on CAD risk. Despite these limitations we
tried to minimize the influence of these stronger risk factors on
Figure 1. Histogram showing the triphasic distribution of PON1-activity according to the PON1-Q192R polymorphism.
doi:10.1371/journal.pone.0006809.g001
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regression analysis in supplementary tables S4-S6). Finally, the
Mendellian randomization analyses in the present study should be
interpreted with caution, since the PON1-activity and CAD risk
association is nonlinear. The concept of Mendelian randomization
is based on several assumptions, including a linear relation
between the trait of interest and disease risk.
Conclusion
We demonstrate a modest and inverse relationship between
PON1-activity and risk of future CAD among apparently healthy
men and women. The PON1-Q192R polymorphism strongly
affects PON1-activity but was not associated with risk of future
CAD. The inconsistency of the relationships among PON1-
genotype, PON1-activity and CAD risk suggests that PON1 is not
a causal factor in the development of CAD. Concurrently, we
observed that the relationship between a proxy for PON1-
concentration and CAD risk was abolished upon adjustment for
HDL-related parameters, indicating that this relationship is
confounded by HDL-cholesterol.
Materials and Methods
The EPIC-Norfolk cohort study is a prospective population
study of 25663 male and female inhabitants of Norfolk, United
Kingdom, aged between 45 and 79 years old. EPIC-Norfolk is part
of the 10-country collaborative EPIC study designed to investigate
dietary and other determinants of cancer. Additional data were
obtained to enable assessment of determinants of other diseases.
Participants were enrolled between 1993 and 1997, completed a
baseline questionnaire survey and attended a clinic visit. The study
cohort was similar to UK population samples with regard to many
characteristics, including anthropometry, blood pressure, and
lipids, but with a lower proportion of smokers. Participants were
recruited by mail from age-gender registers of general practices. At
the baseline survey between 1993 and 1997, participants
completed a detailed health and lifestyle questionnaire, and
additional data collection was performed by trained nurses at a
clinic visit as described previously. All individuals have been
flagged for mortality at the UK Office of National Statistics, with
vital status ascertained for the entire cohort. Death certificates of
individuals enrolled in the study were used to classify the deaths.
The death certificates were coded by trained nosologists according
to the International Classification of Diseases (ICD) 9
th revision.
Death was considered due to CAD if the underlying cause was
coded as ICD 410 to 414. In addition, participants admitted to a
hospital were identified by their unique National Health Service
number by data linkage with ENCORE (East Norfolk Health
Authority database), which identifies all hospital contacts through-
out England and Wales for Norfolk residents. Participants were
identified as having CAD during follow-up if they had a hospital
admission and/or died with CAD listed as an underlying cause.
We report results with follow-up up to January 2003, an average of
6 years. The Norwich District Health Authority Ethics Committee
approved the study, and all participants gave signed informed
consent.
Figure 2. Histogram showing the normal distribution of PON1-activity after adjusting for the PON1-Q192R polymorphism.
doi:10.1371/journal.pone.0006809.g002
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For the present nested case-control study, we identified study
participants who did not report a history of heart attack or stroke
at the baseline clinic visit. A total of 1138 apparently healthy
individuals developed fatal or nonfatal CAD during follow-up. A
total of 2237 controls were apparently healthy study participants
who remained free of CAD during follow-up. 1099 cases were
matched to two controls and 39 cases were matched to one control
by sex, age (within 5 years), and date of visit (within 3 months).
Data on PON1-activity was available in all study subjects, but data
on PON1-genotype was missing in 61 cases.
Biochemical Analyses
Non-fasting blood samples were taken by vein puncture into
serum tubes. Serum levels of total cholesterol, HDL cholesterol,
and triglycerides were measured on fresh samples with the RA
1000 auto-analyzer (Bayer Diagnostics, Basingstoke, United
Kingdom). LDL-cholesterol levels were calculated with the
Friedewald formula [20]. Blood samples were also stored at minus
80u Celsius. Samples were later thawed and processed for analysis.
Serum levels of apolipoproteinA-I (apoA-I) and B (apoB) were
measured by rate immunonephelometry (Behring Nephelometer
BNII, Marburg, Germany) with calibration traceable to the
International Federation of Clinical Chemistry primary standards
[21]. The interassay coefficients of variation of the apoA-I and
apoB measurements were 5% and 3%, respectively. HDL-particle
number and HDL-size were measured with an automated nuclear
magnetic resonance spectroscopic assay as described previously
[22]. C-reactive protein (CRP) levels were measured as described
previously [23]. Serum PON1-activity toward paraoxon was
analyzed as previously described [14]. Serum concentration of
myeloperoxidase (MPO) was measured by use of a commercially
available ELISA (CardioMPO Test, Prognostix, Cleveland, Ohio).
Samples were analyzed in random order to avoid systematic bias.
Researchers and laboratory personnel had no access to identifiable
information and could identify samples by number only.
PON1 Genotyping
We investigated the two most common single nucleotide
polymorphisms (SNP) in the PON1-gene; two substitutions in
Table 4. Distribution of cardiovascular risk factors by quartiles of PON1-activity adjusted for PON1-192 genotype.
PON1-activity adjusted for
PON1-192 genotype (AU/l) 1
st quartile 2
nd quartile 3
rd quartile 4
th quartile P R P{
Variable (,216.8) (216.8 to –7.8) (27.8 to 5.6) (.5.6)
Total no. of patients 856 817 812 826 – – –
Age, years 66.267.4 65.268.0 65.067.8 64.867.9 0.001 20.066 ,0.0001
Women, n (%) 239 (34) 259 (48) 338 (38) 360 (51) ,0.0001* 0.144 ,0.0001
Body mass index, kg/m2 26.763.6 26.763.7 26.563.6 26.763.7 0.7 20.007 0.7
Waist circumference, cm 93.5611.2 93.0611.7 91.2611.9 91.7611.4 ,0.0001 20.073 ,0.0001
Cigarette smoking 0.1* – –
-Never smoked, n 292 299 314 322 – – –
-Previous smoker, n 447 418 411 422 – – –
-Current smoker, n 109 88 76 77 – – –
Alcohol use, units/week 6.167.9 7.169.8 7.4610.3 7.9610.6 0.001 0.041 0.02
Vitamin supplement use, n (%) 344 (43) 333 (45) 380 (50) 360 (47) 0.03* – –
Plasma Vitamin C, mmol/l 49.9619.9 51.7620.2 47.7619.5 52.0619.1 ,0.0001 0.104 ,0.0001
Diabetes mellitus, n (%) 40 (5) 27 (4) 26 (3) 20 (3) 0.08* – –
Systolic blood pressure, mmHg 141618 140619 141618 141618 0.4 20.003 0.8
Diastolic blood pressure, mmHg 84611 84612 85611 84611 0.4 20.002 0.9
Total cholesterol, mmol/l 6.161.1 6.361.1 6.561.2 6.661.3 ,0.0001 0.165 ,0.0001
LDL-cholesterol, mmol/l 4.061.0 4.161.0 4.261.0 4.261.0 ,0.0001 0.086 ,0.0001
HDL-cholesterol, mmol/l 1.2160.35 1.2960.36 1.4060.40 1.4660.41 ,0.0001 0.257 ,0.0001
Triglycerides, mmol/l 1.7 (1.1–3.0) 1.7 (1.1–2.9) 1.7 (1.1–2.9) 1.8 (0.5–3.1) 0.5 0.008 0.6
Apolipoprotein B, mg/dl 132634 132631 132632 134633 0.5 0.027 0.1
Apolipoprotein A-I, mg/dl 152629 157628 162628 168630 ,0.0001 0.208 ,0.0001
HDL size, nm 8.860.5 8.960.5 8.960.5 8.960.5 ,0.0001 0.120 ,0.0001
HDL particle number, nmol/L 32.065.5 33.065.1 34.565.4 36.065.7 ,0.0001 0.269 ,0.0001
C-reactive protein, mg/l 2.0 (1.2–6.0) 1.7 (1.1–4.6) 1.5 (1.0–3.9) 1.7 (0.1–4.4) ,0.0001 20.059 0.001
Myeloperoxidase, pmol/l 626 (14–1238) 576 (24–1118) 523 (25–1015) 515 (25–1004) ,0.0001 20.103 ,0.0001
Paraoxonase activity, U/L 40.6623.7 35.8622.8 50.1625.3 121.8642.2 ,0.0001 0.665 ,0.0001
Values are mean (6SD) or number (percentage). Data for C-reative protein, meyloperoxidase and triglycerides are presented as median (6interquartile range). P=p-
value for linearity between PON1-192 genotype adjusted PON1-activity quartiles and risk factor levels; R=Pearson’s (parametric variables) or Spearman correlation (non-
parametric variables e.g. C-reactive protein, meyloperoxidase and triglycerides) between PON1-192 genotype adjusted serum PON1 activity levels and risk factors, and
the corresponding p-value (P
{). LDL=low-density lipoprotein, HDL=high-density lipoprotein. * indicates p-value by chi square test for dichotomous variables.
doi:10.1371/journal.pone.0006809.t004
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L55M, rs854560, within exon 3 of the PON1 locus) were
analyzed. Genotyping for rs662 and rs854560 was conducted by
KBioscience (http://www.kbioscience.co.uk) using KASPar tech-
nology. Cases and controls were randomly allocated across DNA
study plates with two duplicate samples and two water controls in
each 96-well plate. Concordancy between duplicate samples was
100% for both SNPs. Both SNPs were in Hardy-Weinberg
equilibrium in control participants (P.0.4).
Statistical Analysis
Baseline characteristics were compared between cases and
controls with a mixed-effects model for continuous variables or
conditional logistic regression for categorical variables. Triglycer-
ides (non-fasting) and CRP levels had a skewed distribution, and
therefore both variables were log-transformed before statistical
analysis. Since the PON1-Q192R polymorphism affects serum
PON1-activity, but not its concentration, we adjusted PON1-
activity for the PON1-Q192R genotype to obtain a proxy for
PON1-concentration. Analyses were performed for both (unad-
justed) PON1-activity and PON1-activity adjusted for the PON1-
Q192R polymorphism.
Associations between PON1-genotype, PON1-activity and
cardiovascular risk factors were assessed with Pearson correlations
for parametric variables and Spearman correlations for non-
parametric variables.
Subsequently, PON1-activity and PON1-activity adjusted for the
PON1-Q192R polymorphism were categorized into (sex-specific)
quartiles based on the distribution in the controls. Mean levels of
cardiovascular risk factors were calculated per quartile. Further,
conditional logistic regression was used to calculate odds ratios (ORs)
and corresponding 95% confidence intervals (CIs) per quartiles of
PON1-activity (6adjustment for PON1-Q192R), as an estimate of the
relative risk of CAD with the lowest quartile as the reference category.
Conditional logistic regression took into account the matching for sex,
age and enrollment time, and ORs were additionally adjusted for
alcohol use, apolipoprotein A-I, body mass index (BMI), CRP,
diabetes mellitus, fasting time, HDL-cholesterol, HDL-particle
number, HDL-size, LDL-cholesterol, MPO, smoking, systolic blood
pressure, plasma vitamin-C, vitamin supplement use, waist circum-
ference and non-fasting triglycerides. ORs were also calculated after
additional adjustment for PON1-L55M genotype. Finally, we
performed stepwise (backward) cox regression analysis for PON1-
activity,PON1-genotype aswell asPON1-activity adjusted for PON1-
genotype to predict the best model for risk of CAD. Statistical analyses
were performed with SPSS software (version 12.0.1).
Supporting Information
Table S1 Sex-specific characteristics of study participants.
Found at: doi:10.1371/journal.pone.0006809.s001 (0.08 MB
DOC)
Table S2 Sex-specific associations of PON1 activity, PON1
genotype and risk factors.
Found at: doi:10.1371/journal.pone.0006809.s002 (0.07 MB
DOC)
Table S3 Sex-specific odds ratios of future coronary artery
disease by quartiles of PON1 activity and by quartiles of PON-1
activity adjusted for PON1-192 genotype.
Found at: doi:10.1371/journal.pone.0006809.s003 (0.06 MB
DOC)
Table S4 Backward Stepwise Cox Regression Analysis: HDL-
cholesterol with all and excluded variables.
Found at: doi:10.1371/journal.pone.0006809.s004 (0.08 MB
DOC)
Table S5 Backward Stepwise Cox Regression Analysis: HDL-
particles with all and excluded variables.
Found at: doi:10.1371/journal.pone.0006809.s005 (0.08 MB
DOC)
Table 5. Risk of future coronary artery disease by quartiles of PON1 activity and by quartiles of PON-1 activity adjusted for PON1-
192 genotype.
A
PON1 activity, U/l 1
st quartile 2
nd quartile 3
rd quartile 4
th quartile P
(,25.9) (25.9–43.0) (43.0–89.9) (.89.9)
Cases / controls 322 / 844 258 / 844 284 / 844 274 / 843
OR unadjusted 1.0 0.70 (0.57–0.86) 0.81 (0.67–0.99) 0.77 (0.63–0.95) 0.06
OR adjusted for HDL parameters, (1) 1.0 0.74 (0.57–0.94) 0.83 (0.65–1.05) 0.79 (0.61–1.02) 0.1
OR adjusted for (1) + risk factors, (2) 1.0 0.73 (0.55–0.98) 0.83 (0.63–1.09) 0.78 (0.58–1.05) 0.2
B
PON1- activity adjusted for PON1-192
genotype, AU/l 1
st quartile 2
nd quartile 3
rd quartile 4
th quartile P
(,216.8) (216.8 to27.8) (27.8 to 5.6) (.5.6)
Cases / controls 310 / 856 291 / 817 249 / 812 260 / 826
OR unadjusted 1.0 0.95 (0.77–1.17) 0.76 (0.61–0.94) 0.79 (0.64–0.98) 0.008
OR adjusted for HDL parameters, (1) 1.0 0.99 (0.80–1.24) 0.85 (0.67–1.06) 0.94 (0.74–1.18) 0.3
OR adjusted for (1) + risk factors, (2) 1.0 1.00 (0.80–1.44) 0.76 (0.61–1.13) 0.83 (0.68–1.28) 0.1
Odds ratios (ORs) for the risk of future CAD events by quartiles of PON1-activity and ORs by quartiles of PON1 activity adjusted for PON1-192 genotype. (1) Adjustment
for HDL parameters (HDL-particle number, HDL-cholesterol, HDL-size and apoA-I), (2) Adjustment for HDL parameters and risk factors (alcohol use, BMI, CRP, diabetes
mellitus, fasting time, LDL cholesterol, myeloperoxidase, smoking, systolic blood pressure, vitamin C, vitamin supplement use, waist circumference, triglycerides). P=p-
value for trend=x
2 linear trend with 1 degree of freedom. AU indicates arbitrary units.
doi:10.1371/journal.pone.0006809.t005
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poproteinA-I with all and excluded variables.
Found at: doi:10.1371/journal.pone.0006809.s006 (0.08 MB
DOC)
Table S7 Distribution of combined PON1-haplotypes and its
effect on HDL-cholesterol, HDL-particles, PON1-acitivity and
PON1-activity adjusted for PON1-192 genotype.
Found at: doi:10.1371/journal.pone.0006809.s007 (0.04 MB
DOC)
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